Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. [SUBSTUDY OF 700216591]

Next Previous
Trial Profile

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. [SUBSTUDY OF 700216591]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Tamoxifen; Trastuzumab
  • Indications Advanced breast cancer; Carcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT-HER2+HR+; ADAPT-TP; WSG-ADAPT-TP

Most Recent Events

  • 27 Feb 2025 Status changed from active, no longer recruiting to completed.
  • 20 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
  • 23 Mar 2023 Planned End Date changed from 1 Oct 2020 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top